New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
07:05 EDTCLDXCelldex price target lowered to $33 from $39 at Cantor
Cantor cut its price target on Celldex after the company discontinued development of CDX-1135 for dense deposit disease following unfavorable data. The firm, however, notes that the company intends to initiate six new clinical trials this year and expand a number of other trials. Cantor believes that this expansion of the company's clinical program will help offset the loss of CDX-1135. Cantor keeps a Buy rating on the shares.
News For CLDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
16:03 EDTCLDXCelldex completes enrollment in Phase 3 ACT IV study
Subscribe for More Information
December 5, 2014
08:44 EDTCLDXCelldex study should increase visibility, partner potential, says Roth Capital
Subscribe for More Information
December 4, 2014
16:09 EDTCLDXCelldex initiates Phase 2 study of Glembatumumab Vedotin
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use